Non-radiographic Axial Spondyloarthritis Clinical Trial
Official title:
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Active Non-Radiographic Axial Spondyloarthritis Subjects
This study is to evaluate the efficacy and safety of SHR0302 in subjects with active non-radiographic axial spondyloarthritis.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 11, 2024 |
Est. primary completion date | August 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Provide signed informed consent. 2. BMI =18 kg/m2. 3. Participant has the clinical diagnosis of nr-axSpA fulfilling the 2009 ASAS classification criteria for axSpA but not meeting the radiologic criterion of the modified New York criteria for AS and have objective signs of active inflammation on magnetic resonance imaging (MRI) or based on high sensitivity C-reactive protein (CRP). 4. Participant must have baseline disease activity as defined by having a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >= 4 and a Patient's Assessment of Total Back Pain score >= 4 based on a 0 - 10 Numeric Rating Scale (NRS) at the Screening and Baseline Visits. 5. Participant has had an inadequate response to at least two Nonsteroidal Anti-inflammatory Drugs (NSAIDs) over an at least 4-week period in total at maximum recommended or tolerated doses, or participant has an intolerance to or contraindication for NSAIDs as defined by the Investigator. 6. If subjects are taking permitted csDMARDs or low-dose corticosteroid orally at baseline, the stable doses should have lasted for more than 4 weeks already. Exclusion Criteria: 1. Pregnant women or refuse to receive contraception during the study. 2. Lab abnormality within 4 weeks of randomization as follows: WBC count <3.0×10^9/L;neutrophil count<1.5×10^9/L;hemoglobin level<90.0 g/L ; platelet count <100×10^9/L; AST or ALT levels greater than the 1.5 times the upper limit of normal; HBsAg or HCV or HIV antibody positivity. 3. History of other autoimmune diseases ; history of cancer or infection including tuberculosis and hepatitis; history of important cardiovascular events or thrombotic diseases. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Jiangsu HengRui Medicine Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS) 40 Response at week 12 | Week 12 | ||
Secondary | Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at week 12 | Week 12 | ||
Secondary | Percentage of Participants With ASAS 20 Response at week 12 | Week 12 | ||
Secondary | Change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at week 12 | Week 12 | ||
Secondary | Percentage of Participants with ASAS 5/6 response at Week 12 and Week 24 | Week 12 and Week 24 | ||
Secondary | Change from baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 12 and Week 24 | Week 12 and Week 24 | ||
Secondary | Change from baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 12 and Week 24 | Week 12 and Week 24 | ||
Secondary | Change from baseline in Short-Form-36-Health Survey (SF-36) at Week 12 and Week 24 | Week 12 and Week 24 | ||
Secondary | Change from baseline in Ankylosing Spondylitis Quality of Life (ASQoL) at Week 12 and Week 24 | Week 12 and Week 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03223012 -
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
|
||
Recruiting |
NCT05622708 -
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
|
Phase 4 | |
Active, not recruiting |
NCT05155098 -
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis
|
||
Active, not recruiting |
NCT04732117 -
Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis
|
Phase 3 | |
Recruiting |
NCT05038189 -
Evaluation of Spine Posture, Trunk Position Sense and Gait in Axial Spondyloarthritis Patients
|
N/A | |
Recruiting |
NCT05242588 -
Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA
|
Phase 2 |